BDPTOTCPharmaceutical PreparationsFiscal year ends December 31
BIOADAPTIVES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00−0.00 (-5.56%)
Close on Oct 19, 2026
- Market cap
- $478.03K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0253 (−93.70%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
BIOADAPTIVES, INC. grew revenue 694.1% to $25.56K over the twelve months to Jun 30, 2026. Free cash flow was -$534.03K.
Revenue
$25.56K
+694.1% vs. a year earlier
Operating income
-$909.20K
TTM Q2 2026
Free cash flow
-$534.03K
FY2025
EPS, diluted
-$0.12
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $478.03K
- P/E ratio
- –
- Price to sales
- 18.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -111.71%
Fundamentals
- Revenue
- $25.56K
- Net income
- -$1.16M
- EPS, diluted
- -$0.12
- Free cash flow
- -$534.03K
- Book value per share
- -$0.01
- Diluted shares
- 281M
Twelve years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$25.56K+694.1% YoY
Gross profit
$19.79K+1761.4% YoY
Operating income
-$909.20K
Net income
-$1.16M
EPS, diluted
-$0.12
Free cash flow
–
Reported periodTrailing twelve months